Keywords: lilly, forteo, lowers, fracture, risk, meantime, phase

Lilly's Forteo lowers fracture risk

Article | 11 May 2001

Meantime, a Phase III clinical study of Eli Lilly's investigational boneformation drug Forteo (teriparatide; parathyroid hormone), administered by injection, has ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Lilly

Go to company listing

Related Drugs

Forteo

Amino Acids

Injection

teriparatide

Physostigmine Salicylate

Go to drug listing